RussellWJenkinsMDPhD

Hematologic Oncology, Melanoma

Instructor

Dr. Jenkins is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
MGH Cancer Center
55 Street, Jackson 904B
Boston, MA 02114
Phone+1 617-726-9372

Fax+1 844-542-5959

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2014 - 2018
Massachusetts General HospitalResidency, Internal Medicine, 2013 - 2014
Massachusetts General HospitalInternship, Internal Medicine, 2012 - 2013
Medical University of South CarolinaClass of 2012

PubMed

894 citations
Mechanisms of resistance to immune checkpoint inhibitors.
Russell W. Jenkins, David A. Barbie, Keith T. Flaherty
British Journal of Cancer. 2018-01-02
625 citations
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.
Moshe Sade-Feldman, Keren Yizhak, Stacey L Bjorgaard, John P Ray, Carl G de Boer
Cell. 2018-11-01
566 citations
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
Livnat Jerby-Arnon, Parin Shah, Michael S. Cuoco, Christopher Rodman, Mei-Ju Su
Cell. 2018-11-01

Journal Articles

Tumor Innate Immunity Primed by Specific Interferon-Stimulated Endogenous Retroviruses
Scott Rodig, Ewa Sicinska, Thanh Uyen Barbie, David Allen Barbie, Russell William Jenkins, Ravindra Uppaluri, Rohit Thummalapalli, Jacob Sands, Nature

Melanoma Research Alliance Announces $8.2 Million for 33 Grant Awards to Advance Melanoma ResearchApril 30th, 2019